We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04697628
Recruitment Status : Recruiting
First Posted : January 6, 2021
Last Update Posted : June 2, 2023
Sponsor:
Collaborator:
Genmab
Information provided by (Responsible Party):
Seagen Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

This trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cervical cancer that has spread to other parts of the body (metastatic) or has come back after being treated (recurrent).

Participants in this trial will be randomly assigned to one of two groups. One group will be treated with tisotumab vedotin. Participants in the other group will get one of five different chemotherapy drugs (topotecan, vinorelbine, gemcitabine, pemetrexed, or irinotecan). Participants and their doctors will know which group they are in. Participants in the chemotherapy group will decide with their study doctor which drug they will take.


Condition or disease Intervention/treatment Phase
Cervical Cancer Drug: tisotumab vedotin Drug: topotecan Drug: vinorelbine Drug: gemcitabine Drug: irinotecan Drug: pemetrexed Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 556 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Actual Study Start Date : February 22, 2021
Estimated Primary Completion Date : May 31, 2024
Estimated Study Completion Date : February 28, 2028

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cervical Cancer

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Tisotumab vedotin
Tisotumab vedotin monotherapy
 Drug: tisotumab vedotin
2.0 mg/kg every 3 weeks (Q3W)
Other Name: TIVDAK
Active Comparator: Chemotherapy
Investigator's choice of one chemotherapy treatment (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed)
 Drug: topotecan
1 or 1.25 mg/m2 intravenous (IV) on Days 1 to 5, every 21 days

Drug: vinorelbine
30 mg/m2 IV on Days 1 and 8, every 21 days

Drug: gemcitabine
1000 mg/m2 IV on Days 1 and 8, every 21 days

Drug: irinotecan
100 or 125 mg/m2 IV weekly for 28 days, every 42 days

Drug: pemetrexed
500 mg/m2 IV on Day 1, every 21 days


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: Up to approximately 2 years ]
    OS is defined as the time from the date of randomization to the date of death due to any cause.


Secondary Outcome Measures :
  1. Progression-free survival (PFS) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by the investigator [ Time Frame: Up to approximately 1 year ]
    PFS per investigator is defined as the time from the date of randomization to the first documentation of disease progression per RECIST v.1.1 by the investigator, or to date of death due to any cause, whichever occurs earlier.

  2. Confirmed objective response rate (ORR) based on RECIST v1.1 as assessed by the investigator [ Time Frame: Up to approximately 6 months ]
    Confirmed objective response rate is defined as the proportion of participants with a confirmed complete response (CR) or partial response (PR) per RECIST v.1.1.

  3. Time-to-response (TTR) as assessed by the investigator [ Time Frame: Up to approximately 6 months ]
    TTR is defined as the time from the date of randomization to the date of first confirmed objective response (CR or PR that is subsequently confirmed). Only participants with confirmed CR or PR will be included in the analysis.

  4. Duration of response (DOR) as assessed by the investigator [ Time Frame: Up to approximately 1 year ]
    DOR is defined as the time from the date of first confirmed objective response (CR or PR that is subsequently confirmed) to the date of first documented PD per RECIST v1.1 or death from any cause, whichever occurs first. Only participants with confirmed CR or PR will be included in the analysis.

  5. Incidence of adverse events (AEs) [ Time Frame: Up to approximately 2 years ]
    Analyses of AEs will be summarized descriptively

  6. Health-related quality of life as assessed by EQ-5D-5L index [ Time Frame: Up to approximately 2 years ]
    EQ-5D-5L is a standardized instrument developed by the EuroQol Group as a measure of HRQOL that can be used in a wide range of health conditions and treatments. The EQ-5D-5L consists of a descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

  7. Health-related quality of life as assessed by EQ-5D visual analog scale (VAS) [ Time Frame: Up to approximately 2 years ]
    EQ-5D-5L is a standardized instrument developed by the EuroQol Group as a measure of HRQOL that can be used in a wide range of health conditions and treatments. The EQ-5D-5L consists of a descriptive system and the EQ VAS. The EQ VAS records the participant's self-rated health on a vertical VAS. This can be used as a quantitative measure of health outcome that reflects the participant's own judgment.

  8. Health-related quality of life as assessed by EORTC-QLQ-C30 [ Time Frame: Up to approximately 6 months ]
    The QLQ-C30 is a validated questionnaire developed by the European Organization for Research and Treatment of Cancer (EORTC) to assess the quality of life of participants with cancer in multicultural clinical research settings.

  9. Health-related quality of life as assessed by EORTC-QLQ-CX24 [ Time Frame: Up to approximately 6 months ]
    The EORTC-QLQ-CX24 is a validated questionnaire developed by the EORTC to assess the quality of life in patients who are treated for cervical cancer both in clinical studies and in clinical practice.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Has recurrent or metastatic cervical cancer with squamous cell, adenocarcinoma, or adenosquamous histology, and:

  • Has experienced disease progression during or after treatment with a standard of care systemic chemotherapy doublet, or platinum-based therapy (if eligible), defined as either:

    • paclitaxel + cisplatin + bevacizumab + anti-PD-(L)1 agent, or
    • paclitaxel + carboplatin + bevacizumab + anti-PD-(L)1 agent, or
    • paclitaxel + topotecan/nogitecan + bevacizumab + anti-PD-(L)1 agent
  • Note: In cases where bevacizumab and/or anti-PD-(L)1 agent is not a standard of care therapy or the participant was ineligible for such treatment according to local standards, prior treatment with bevacizumab and/or anti-PD-(L)1 agent is not required.
  • Has received 1 or 2 prior systemic therapy regimens for recurrent and/or metastatic cervical cancer. Chemotherapy administered in the adjuvant or neoadjuvant setting, or in combination with radiation therapy, should not be counted as a systemic therapy regimen. Single agent therapy with an anti-PD(L)1 agent for r/mCC cancer should be counted.
  • Measurable disease according to RECIST v1.1 as assessed by the investigator.
  • Has ECOG performance status of 0 or 1 prior to randomization.
  • Has life expectancy of at least 3 months.

Exclusion Criteria

  • Has primary neuroendocrine, lymphoid, sarcomatoid, or other histologies not mentioned as part of the inclusion criteria above.
  • Has clinically significant bleeding issues or risks. This includes known past or current coagulation defects leading to an increased risk of bleeding; diffuse alveolar hemorrhage from vasculitis; known bleeding diathesis; ongoing major bleeding; trauma with increased risk of life-threatening bleeding or history of severe head trauma or intracranial surgery within 8 weeks of trial entry.
  • Has any history of intracerebral arteriovenous malformation, cerebral aneurysm, or stroke (transient ischemic attack >1 month prior to screening is allowed).
  • Active ocular surface disease or a history of cicatricial conjunctivitis or inflammatory conditions that predispose to cicatrizing conjunctivitis (e.g. Wagner syndrome, atopic keratoconjunctivitis, autoimmune disease affecting the eyes), ocular Stevens-Johnson syndrome or toxic epidermal necrolysis, mucus pemphigoid, and participants with penetrating ocular transplants. Cataracts alone is not an exclusion criterion.
  • Major surgery within 4 weeks or minor surgery within 7 days prior to the first study treatment administration.
  • Peripheral neuropathy ≥grade 2.
  • Any prior treatment with monomethyl auristatin E (MMAE)-containing drugs.

There are additional inclusion and exclusion criteria. The study center will determine if criteria for participation are met.

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04697628


Contacts
Layout table for location contacts
Contact: Seagen Trial Information Support 8663337436 clinicaltrials@seagen.com

Locations
Show Show 177 study locations
Sponsors and Collaborators
Seagen Inc.
Genmab
Investigators
Layout table for investigator information
Study Director: Leo Nicacio, MD Seagen Inc.
Study Director: Liz Whalley, PhD Seagen Inc.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Seagen Inc.
ClinicalTrials.gov Identifier: NCT04697628    
Other Study ID Numbers: SGNTV-003
ENGOT cx-12 ( Other Identifier: European Network of Gynaecological Oncological Trial )
GOG-3057 ( Other Identifier: GOG Foundation )
First Posted: January 6, 2021    Key Record Dates
Last Update Posted: June 2, 2023
Last Verified: May 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Seagen Inc.:
Seattle Genetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Tisotumab vedotin
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Urogenital Diseases
Genital Diseases
Gemcitabine
 Irinotecan
Pemetrexed
Topotecan
Vinorelbine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors
Antineoplastic Agents, Phytogenic
Tubulin Modulators